MRT67307
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


MRT67307
Description :
MRT67307 is a dual inhibitor of the IKKε and TBK-1 with IC50s of 160 and 19 nM, respectively[1]. MRT67307 also inhibits ULK1 and ULK2 with IC50s of 45 and 38 nM, respectively. MRT67307 also blocks autophagy in cells[2].UNSPSC :
12352005Hazard Statement :
H302, H315, H319, H335Target :
Autophagy; IKK; ULKType :
Reference compoundRelated Pathways :
Autophagy; NF-κBApplications :
COVID-19-immunoregulationField of Research :
Cancer; Inflammation/ImmunologyAssay Protocol :
https://www.medchemexpress.com/MRT67307.htmlConcentration :
10mMPurity :
99.56Solubility :
DMSO : 100 mg/mL (ultrasonic)Smiles :
O=C(NCCCNC1=NC(NC2=CC=CC(CN3CCOCC3)=C2)=NC=C1C4CC4)C5CCC5Molecular Formula :
C26H36N6O2Molecular Weight :
464.60Precautions :
H302, H315, H319, H335References & Citations :
[1]Clark K, et al. Novel cross-talk within the IKK family controls innate immunity. Biochem J. 2011 Feb 15;434 (1) :93-104.|[2]Petherick KJ, et al. Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR) -dependent autophagy. J Biol Chem. 2015 May 1;290 (18) :11376-83.|[3]Zhu Z, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. 26.37Cancer Discov. 2014 Apr;4 (4) :452-65.Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
Reference compound1Clinical Information :
No Development ReportedIsoform :
IKKε; TBK1; ULK1; ULK2CAS Number :
[1190378-57-4]

